Gainers
• Corvus Pharmaceuticals, Inc. CRVS stock moved upwards by 97.44% to $5.41 during Tuesday's pre-market session.
• Endologix, Inc. ELGX stock moved upwards by 45.55% to $0.37. According to the most recent rating by BTIG, on May 12, the current rating is at Neutral.
• AEterna Zentaris, Inc. AEZS stock moved upwards by 39.32% to $0.58.
• Novavax, Inc. NVAX shares rose 35.44% to $107.60. The most recent rating by B. Riley FBR, on Jun 29, is at Buy, with a price target of $106.
• Endo International, Inc. ENDP shares rose 17.56% to $4.25. The most recent rating by Piper Sandler, on Apr 15, is at Overweight, with a price target of $6.
• ObsEva, Inc. OBSV shares increased by 14.02% to $3.70. The most recent rating by BMO Capital, on Jul 7, is at Market Perform, with a price target of $4.
• Vaxart, Inc. VXRT stock moved upwards by 13.35% to $7.30. The most recent rating by HC Wainwright & Co., on Apr 30, is at Buy, with a price target of $7.
• Otonomy, Inc. OTIC stock increased by 12.57% to $3.58. The most recent rating by Cantor Fitzgerald, on Jun 16, is at Overweight, with a price target of $9.
• BELLUS Health, Inc. BLU shares rose 9.11% to $3.71. The most recent rating by HC Wainwright & Co., on Jun 26, is at Buy, with a price target of $28.
• Livongo Health, Inc. LVGO shares rose 7.92% to $83.78. The most recent rating by Stephens & Co., on Jul 7, is at Overweight, with a price target of $95.
Losers
• Evolus, Inc. EOLS shares fell 39.85% to $3.20 during Tuesday's pre-market session. The most recent rating by Mizuho, on May 12, is at Buy, with a price target of $8.
• Unum Therapeutics, Inc. UMRX stock fell 17.73% to $1.81.
• Cellectis, Inc. CLLS shares declined 15.44% to $16.11.
• Aptorum Group, Inc. APM stock decreased by 6.67% to $3.36.
• resTORbio, Inc. TORC stock decreased by 5.23% to $2.36. The most recent rating by Evercore ISI Group, on Apr 30, is at Outperform, with a price target of $4.
• Lianluo Smart, Inc. LLIT shares fell 4.37% to $0.66.
• 9 Meters Biopharma, Inc. NMTR stock fell 3.48% to $0.60.
• HTG Molecular Diagnostics, Inc. HTGM shares declined 3.23% to $0.60. The most recent rating by HC Wainwright & Co., on May 14, is at Buy, with a price target of $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.